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Abstract: Conjugated fatty acids (CFA) have received increased interest because of their 
beneficial effects on human health, including preventing cancer development. Conjugated 
linoleic acids (CLA) are such CFA, and have been reviewed extensively for their multiple 
biological activities. In contrast to other types of CFAs including CLA that are found at 
low concentrations (less than 1%) in natural products, conjugated linolenic acids (CLN) are 
the only CFAs that occur in higher quantities in natural products. Some plant seeds contain 
a considerably high concentration of CLN (30 to 70 wt% lipid). Our research group has 
screened CLN from different plant seed oils to determine their cancer chemopreventive 
ability. This review describes the physiological functions of CLN isomers that occur in 
certain plant seeds. CLN are able to induce apoptosis through decrease of Bcl-2 protein in 
certain human cancer cell lines, increase expression of peroxisome proliferator-activated 
receptor (PPAR)-γ, and up-regulate gene expression of p53. Findings in our preclinical 
animal studies have indicated that feeding with CLN resulted in inhibition of colorectal 
tumorigenesis through modulation of apoptosis and expression of PPARγ and p53. In this 
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review, we summarize chemopreventive efficacy of CLN against cancer development, 
especially colorectal cancer. 
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1. Introduction 
Several fatty acids with conjugated double bonds are present in nature. These conjugated fatty acids 
(CFA) include conjugated dienes, trienes, and tetraenes. Examples are edible fats of ruminant origin, 
such as milk fat, tallow that contain conjugated linoleic acids (CLA) [1]. Many plant seed oils also 
contain conjugated trienoic fatty acids in the form of conjugated linolenic acids (CLN) [2,3]. In 
addition, aquatic plants including seaweeds contain conjugated polyenes in the forms of conjugated 
eicosapentaenoic acid (CEPA) and conjugated arachidonic acid (CAA) [4–6]. 
Most CFAs are 18-carbon compounds originating from oleic, linoleic, linolenic, and stearidonic 
acids. They occur in terrestrial plant lipids, especially seed oils, and include dienes, trienes, and 
tertraenes. The conjugated trienoic fatty acids from plant are mainly α-eleostearic acid   
(9c,11t,13t-18:3), catalpic acid (9t,11t-13c-18:3), punicic acid (9c,11t,13c-18:3), calendic acid 
(8t,10t,12c-18:3), and jacaric acid (8c,10t,12c-18:3) [7] (Figure 1). Calendic acid occurs in pot 
marigold seed oil, punicic acid in pomegranate seed oil, and α-eleostearic acid in tung and bitter gourd 
seed oils [8].  Main CLN of the plant seed oils are c,t,c, c,t,t, or t,t,c-isomers. Minor fatty acids,   
β-eleostearic acid (9t,11t,13t-18:3) and β-calendic acid (8t,10t,12t-18:3), are also present in some seed 
oils [8]. α-Eleostearic acid is the principal component of bitter gourd seed oil by contributing to more 
than 50% of oil; but the flesh of the bitter gourd contains catalpic acid [9]. 
A well-known conjugated diene and tetraene of plant origin is 10t 12t-18:2 [10] and α-parinaric acid 
(9c,11t,13t,15c-18:4) [11,12]. There are no reports on the occurrence of CFA  with more than   
18 carbon atoms in lipids of plant origin, and the major source of all these conjugated trienoic fatty 
acids may be seed oils. Most of seed oils contain positional and geometrical isomers of linolenic acid 
(18:3) with conjugated double bonds that is often referred to CLN. Unlike CLA that occurs at 
concentrations of less than 1% in nature, extremely high amounts  of naturally occurring CLN is 
present in some seed oils. For example, 62.2% of pot marigold seed oil is calendic acid   
(8t,10t,12c-18:3), 83% of pomegranate seed oil is punicic acid (9c,11t,13c-18:3), 67.7% of tung seed 
oil and 56.2% of bitter gourd seed oil is α-eleostearic acid (9c,11t,13t-18:3), and 42.3% of catalpa see 
oil is catalpic acid (9t,11t,13c-18:3) [8]. Among seed oils that are sources of CLN, bitter gourd and 
pomegranate are edible plants, and catalpa is often used as Chinese medicine. 
Although the bioactive properties of the CLA isomers have long been recognized [13,14], CLN 
have recently shown potent bioactivity. In a large number of in vitro and in vivo studies [15–18], CLN 
have displayed potent anti-inflammatory, immunomodulatory, anti-obese and anti-carcinogenic 
activities, along with the ability to improve biomarkers of cardio-vascular health. CLN isomers are 
naturally present in high concentrations in a large variety of seed oils and can also be produced in vitro 
by strains of lactobacilli and bifidobactena through the activity of the enzyme linoleic acid isomerase 
on α-linolenic acid [15,19]. In this review, we will summarize our findings in several studies showing Int. J. Mol. Sci. 2011, 12                       
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possible cancer chemopreventive activities of CLN against colorectal cancer (CRC) and the 
mechanisms through which the activities are mediated. 
Figure 1. Conjugated linolenic acids (CLN) present in plant seed oils. 
 
 
2. CLN Inhibits Colon Carcinogenesis in Vivo Studies 
About 30% of human cancers are considered to be associated with dietary habits and lifestyle. In 
particular, the amount and type of dietary fat influence development of certain types of cancer, such as 
colorectal malignancy [20–23]. CRC that is more common in developed countries is the third most 
commonly diagnosed cancer in the world [24]. In 2008, GLOBOCAN estimated that 1.23 million new 
cases of CRC were clinically diagnosed and killed more than 600,000 people [24]. It is well-known 
that CRC is linked to Western lifestyle, which often includes intake of high-fat diets, and the amount Int. J. Mol. Sci. 2011, 12                       
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and type of dietary fat consumed are of particular importance for development of CRC [22,25–29]. 
Epidemiological studies suggest that high intake of fish and fish oil rich in n-3 polyunsaturated fatty 
acids (PUFA) correlates with a reduced risk of colorectal malignancy. Laboratory animal 
carcinogenesis studies indicate that n-3 PUFA are protective, whereas n-6 PUFA promote colorectal 
oncogenesis The mechanisms of protection by n-3 PUFA is mainly due to their interference with 
biosynthesis of two-series of prostaglandins (PGs) from arachidonic acid [30]. 
In a short-term animal study, dietary feeding with bitter gourd (Momordica charantia) seed oil 
(BGO) for 5 weeks at three dose levels (0.01, 0.1, and 1%) caused a significant reduction in the 
frequency of colonic aberrant crypt foci (ACF, Figure 2a), which are putative precursor lesions for 
CRC [31,32], in rats initiated with a colonic carcinogen, azoxymethane (AOM) [33]. A significant 
reduction in the multiplicity of ACF (Figure 3a) was found in rats fed the diet containing 0.01% BGO, 
in which 0.006% CLN (9c,11t,13t-18:3) was present. In another experiment, all three dose levels (0.01, 
0.1, and 1%) of dietary administration with catalpa (Catalpa ovata) seed oil (CPO) that contains a 
large amount of catalpic acid (9t,11t,13c-18:3)  for 5 weeks significantly  inhibited ACF formation 
induced by AOM when compared to rats treated with AOM alone [34] (Figure 3b). Importantly, these 
studies showed that the diets containing BGO or CPO did not affect normal growth of colonic crypts 
and histology of liver, such as fatty liver. This may be explained by the findings in another   
in vivo study demonstrating that the BGO-containing diets significantly reduced free cholesterol levels 
with a trend toward an increase in high density lipoprotein, but did not affect the total cholesterol  
level [35]. Cell proliferation plays an important role in multistage carcinogenesis with multiple genetic 
changes. Dietary feeding with BGO or CPO lowered cell proliferation of ACF as well as normal 
appearing crypts of rats that received AOM, where the lesions and crypts were hyper-proliferation 
status due to injection of a colonic carcinogen, AOM [33,34]. Other natural compounds [36–38] and 
retinoids [39] that are potential cancer chmeopreventive agents possess similar effects [40–42]. As to 
the effects of BGO and CPO on apoptosis in the ACF, feeding with BGO or CPO increased apoptotic 
cells in ACF [33,34]. These findings were consistent with the anti-proliferative and apoptosis-inducing 
effects of CLN found in vitro studies with human colon cancer cell lines [43–45]. 
In a subsequent long-term in vivo assay, we confirmed chemopreventive ability of BGO against 
CRC development in rats [46]. Dietary administration of BGO rich in CLN (9c,11t,13t-18:3)  for  
32 weeks significantly lowered the incidence of colonic adenoma (Figure 2b) and adenocarcinoma 
(Figure 2c) induced by AOM in rats without causing any adverse effects (Figure 4a). The multiplicities 
(number of adenocarcinoma per rat) of CRC were also reduced when fed the BGO-containing diets at 
all three dose levels (0.01, 0.1, and 1%) (Figure 4b). Pomegranate (Punica granatum L.) seed oil 
(PGO) rich in other CLN isomer (9c,11t,13c-18:3) that was given to rats in their diet for 32 weeks also 
inhibited AOM-induced colorectal carcinogenesis, as estimated by the occurrence of colorectal 
adenocarcinoma (Figure 4c,d) [47]. Although the protective effects of BGO and PGO against CRC 
development were not dose-dependent, dietary feeding with BGO and PGO during the post-initiation 
stage suppressed progression of adenoma to malignant epithelial neoplasm (adenocarcinoma) [46,47]. 
In the long-term in vivo studies, we found interesting findings that dietary feeding with BGO or PGO 
increased expression of peroxisome proliferator-activated receptor (PPAR)-γ expression in the colonic 
mucosa [46,47]. PPARs that are members of the nuclear receptor superfamily have three different 
isoforms: PPARα, PPARδ, and PPARγ PPARs are ligand-activated transcription factors, and they are Int. J. Mol. Sci. 2011, 12                       
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implicated in tumor progression, differentiation, and apoptosis. PPAR ligands are reported to activate 
PPAR signaling and exert cancer prevention and treatment in vitro and/or in vivo studies [48–50]. The 
findings are consistent with that in vitro studies using human CRC cell lines [44,45], where CLN 
(9c,11t,13t-18:3) was able to induce apoptosis in human colon cancer cells and enhance PPARγ 
expression in the CRC cells. Lipid peroxidation may be another possible explanation for the inhibitory 
effects of BGO and PGO on colorectal carcinogenesis [51]. Human CRC cells, DLD-1, were inoculated 
into nude mice, and then they were gavaged with CLA (9c,11t-  and 10t,12c-18:2) and CLN   
(9c,11t,13t-18:3). The CLA and CLN treatments resulted in retardation of tumor growth, and the 
inhibitory effects of tumor growth was strong in the order of CLN >9c,11t-CLA > 10t,12c-CLA. CLN 
treatment caused DNA fragmentation and increased lipid peroxidation in tumor cells. Similar findings 
were observed in other study on the effects of CEPA [52], where CEPA had extremely strong anti-tumor 
effects on transplanted tumor cells, when compared to CEPA and CLA. In the tumor cells inoculated 
into the mice, the membranous phospholipid hydroperoxide and thiobarbituric acid reactive substances 
(TBARS) levels increased, when mice were given CEPA, suggesting the involvement of lipid 
peroxidation in the anti-carcinogenic effects of CEPA. 
Figure 2. Colonic preneoplastic and neoplastic lesions induced by a colonic carcinogen, 
azoxymethane (AOM). (a) Aberrant crypt foci (ACF, circled) on colonic mucosa stained 
with methylene blue; (b) Tubular adenoma; (c) Tubular adenocarcinoma. ((a) Methylene 
blue stain; (b) and (c) Hematoxylin and eosin-stain; Bars: (a) (c) 500 m; (b) 200 m). 
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Figure 3. The numbers of aberrant crypt foci (ACF) induced by azoxymethane (AOM) 
from in vivo short-term assays determining the effects of 5-week feeding with (a) Bitter 
gourd (Momordica charantia) seed oil (BGO) and (b) Catalpa (Catalpa ovata) seed oil 
(CPO) in rats. 
 
Figure 4. The  incidences and multiplicities  of adenocarcinoma (ADC) induced by 
azoxymethane (AOM) in vivo long-term assays determining the effects of 32-week feeding 
with (a) (b) BGO and (c) (d) PGO in rats. (a) (c) the incidences of ADC; and (b) (d) the 
multiplicities of ADC. 
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In vivo experimental animal studies demonstrating that dietary feeding with BGO [33,46], PGO [47], 
and CPO [34] exerts their chemopreventive activities in rat colorectal carcinogenesis, CLA isomers 
(9c,11t-18:2 for BGO and PGO; and 9t, 11t-18:2 for CPO) were detected in the liver lipids of rats fed 
with CLN [35,53]. CLA is a powerful anti-carcinogenesis agent in the rat mammary carcinogenesis 
with an effective range of 0.1 to 1.0% in the diet [54–56]. Therefore, the potential cancer 
chemopreventive effects of CLN are considered to be partly due to the presence of CLA isomers 
derived from CLN. A possible pathway for the formation of CLA in the liver lipids of rats fed BGO, 
PGO, and CPO is the bioconversion of CLN (9c,11t,13t-18:3, 9c,11t,13c-18:3, and 9t,11t,13c-18:3) to 
CLA (9c,11t-18:2 and 9t,11t-18:2) [35,53], but this bioconversion has not been confirmed in human. 
Although this may contribute to the inhibitory effects of CLN on colorectal carcinogenesis, other 
factors such as direct action of CLN as PPARγ ligand [46,47] and acceleration of lipid peroxidation 
followed by apoptosis [51] should be taken into account because powerful cancer chemopreventive 
activity of CLN at low dose levels was observed in our colorectal carcinogenesis studies [33,46,47]. 
Also, other mechanisms, including anti-inflammatory action, are considered for the inhibitory effects 
of CLN on colorectal carcinogenesis [32,48,57]. 
3. Growth-Inhibitory Effects of CLN in Vitro Studies 
Naturally occurring CLN inhibit growth of variety of cancer cells and difference in activity was 
observed among different CLN isomers. Calendic acid (8t,10t,12c-18:3) from pot marigold did not 
affect the growth of SV-T2, SV40-transformed mouse fibroblasts, but α-eleostearic acid   
(9c,11t,13t-18:3), catalpic acid (91,11t,13c-18:3), and punicic acid (9c,11t,13c-18:3) were cytotoxic to 
the cells [58]. Similar anti-growth effects of α-eleostearic, catalpic, and punicic acids were observed in 
case of human monocytic leukemia cell line, U-937 [58]. Difference in cis/trans configuration among 
the CLN isomers did not influence their cytotoxicic ability. Also, the growth inhibitory effects of each 
9,11,13-CLN isomer with either c-t-c, c-t-t or t-t-c configuration was greatly enhanced by adding an 
antioxidant, butylated hydroxytoluene to fatty acid [58]. This suggests involvement of lipid 
peroxidation in the cytotoxic effects of 9,11,13-CLN on human cancer cells. The oxidative stabilities 
of three types of 9,11,13-18:3 isomers were comparable, but was lower than the 8t,10t,12c-18:3 isomer [58]. 
Therefore, the cytotoxity of 9,11,13-18:3 that was greater than 8.10,12-18:3 may be partly due to their 
different susceptibilities to peroxidation [58]. 
The cytotoxic and anti-growth effects of CLN were also observed other human cancer cell lines, 
DLD-1 (colorectal adenocarcinoma), HepG2 (well-differentiated hepatocellular carcinoma),  A549 
(lung alveolar cell carcinoma), and HL-60 (acute promyelocytic leukemia) [51]. A fatty acid mixture 
rich in CLN (α-elcostcaric acid; 9c,11t,13t-18:3) showed dose-dependent growth-inhibitory effects via 
activation of the apoptotic pathway. The effects on a human CRC cell line (DLD-1) were stronger than 
two CLA isomers, 9c,11t-18:2 and 10t,12c-18:2. In the assays, the apoptotic promoting factors, 
caspases were activated by adding of α-eleostearic acid-rich fatty acid mixture to DLD-1 cells. The 
treatment with the fatty acid mixture resulted in an increase of amounts of membrane phospholipid 
peroxidation in DLD-1 cells, as measured by the TBARS values. In contrast, addition of α-tocopherol 
suppressed oxidative stress and apoptosis that were induced by α-eleostearic acid-rich fatty acid mixture. Int. J. Mol. Sci. 2011, 12                       
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The mechanisms underlying the cytotoxicity and apoptosis induced by α-eleostearic acid in Caco-2 
cells (human colorectal adenocarcinoma) is suspected to be modulation of lipid peroxidation. However, 
the cytotoxic effects of β-eleostearic acid and β-calendic acid, which have all-trans-conjugated double 
bonds, were not completely reduced in the presence of α-tocopherol. This may suggest the presence of 
pathway(s) other than lipid peroxidation in the reduction of cell viability of Caco-2 cells by   
β-eleostearic and β-calendic acids. On the other hand, the cytotoxic effects of β-eleostearic acid on 
DLD-1 cells were not observed when α-tocopherol was added. Therefore, the metabolic and signal 
transduction systems in Caco-2 cells may contribute to different anti-cancer and anti-growth effects 
among CLN isomers, suggesting that further investigations are required for a better understanding of 
the specific mechanisms underlying the cytotoxic and apoptosis-inducing effects of β-eleostearic and 
β-calendic acids. 
Major CLN present in the plant seed oils are c,t,c, c,t,t, or t,t,c-isomers. In addition, β-eleostearic 
acid (9t,11t,13t-18:3) and β-calendic acid (8t,10t,12t-18:3) are also present in some seed oils as minor 
fatty acids [8]. These all-trans-CLN isomers are contained as mixtures of CLN that are 
chemosynthesized by alkaline isomerization of linolenic acid [59]. Growth inhibition effects and 
induction of DNA fragmentation by β-eleostearic acid and β-calendic acids in Caco-2 cells were 
greater than α-eleostearic and α-calendic acids with cis configuration [43]. Furthermore, down-regulation 
of an anti-apoptotic protein bcl-2 mRNA and up-regulation of a pro-apoptotic protein bax mRNA in 
Caco-2 cells by β-eleostearic acid were greater than that by α-eleostearic acid. These findings indicate 
that the configuration of conjugated double bonds is important in cytotoxicity and apoptosis induced 
by CLN in Caco-2 cells and all-trans-CLN isomers act as more effective tumor-growth inhibitory 
compounds. When compared to CLA isomers with cis configuration, the greater tumor-inhibitory and 
apoptosis-inducing effects by all trans isomer of CLA on human CRC cell lines were demonstrated in 
a report by Beppu et al. [60]. In their study, three different human CRC cell lines, Caco-2, HT-29, and 
DLD-1, were incubated with 9c,11c-18:2, 9c,11t-18:2, 10t,12c-18:2 or 9t,11t-18:2, the strongest effect 
was observed in the treatment with 9t,11t-18:2, followed by 10t,12c-18:2, 9c,11c-18:2, and   
9c,11t-18:2. 
4. Molecular Mechanisms by Which CLN Exert Anti-Carcinogenesis and Anti-Tumor Growth Effects 
The anti-carcinogenic effects of CLN and CLA have further been confirmed by Yasui et al. [45]. In 
their study, free fatty acids prepared from BGO (BGO-FFA) containing more than 60%   
α-eleostearic acid (9c,11t,l3t-l8:3) exhibited strong tumor-growth inhibition and apoptosis induction in 
three human CRC cell lines, DLD-1, HT-29, and Caco-2, the effects being greater than CLA   
(9c,11t-18:2). The study also demonstrated that the inhibitory effects of CLN were associated with 
modulation of PPAR-γ expression, which is one of the target molecules for suppressing development 
of cancer and other chronic diseases [48–50,61,62]. The treatment with BGO-FFA in Caco-2 cells 
resulted in approximately 3-fold increase in the expression of PPARγ protein in a dose-dependent 
manner, which was greater than an increase (1.5-fold) by troglitazone [45]. Cancer-retardant activity of 
CLA has also been reported to be associated with its ability to activate PPARγ  [63]. PPARγ  is 
predominantly found in normal adipose tissue [64], but is also expressed in cancer cells developed in a 
variety of tissues, including colorectum [65,66], breast [67], prostate [68], and tongue [69]. PPARγ Int. J. Mol. Sci. 2011, 12                       
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activation induces growth arrest and apoptosis in CRC [70,71] and breast cancer cell lines [72]. In 
experimental colorectal carcinogenesis, a specific PPARγ ligand, troglitazone, effectively suppresses the 
development of ACF initiated with AOM and promoted with dextran sodium sulfate in rats [50,73]. 
PPARγ ligands, such as troglitazone and 15-deoxy-delta12,14-prostaglandin J2 (15-d-PGJ2), cause 
growth-inhibition and induction of apoptosis in human cancer cell lines [71,72,74]. 
In another study by Yasui et al., the effects (reduction of cell viability and apoptosis induction) of 
CLN (9c,11t,13t-18:3) on the growth of HT-29 cells were much greater than that found in Caco-2 cells [44]. 
In general, expression of the PPARγ protein in HT-29 and DLD-1 cells is higher than that of Caco-2 
cells. Therefore, 9c,11t,13t-18:3 as well as troglitazone arc more effective in growth inhibition and 
apoptosis induction of CRC cells with highly expressed PPARγ protein. HT-29, Caco-2, and DLD-1 
cells are poorly differentiated, well-differentiated moderately differentiated adenocarcinomas, 
respectively [75,76]. Combination treatments with irinotecan and 5-fluorouracil resulted in different 
anti-cancer effect among CRC cell lines [77]. The differential responses of 9c,11t,13t-18:3 and 
troglitazone against HT-29, Caco-2  and DLD-1 cell lines may be depend on differences in cell 
differentiation of adenocarcinoma cells and PPARγ expression level. 
The p53, growth-arrest, and GADD45 play important roles in the pathways of growth-inhibition 
and apoptosis induction in a variety of cancer cells [78,79]. Interestingly, the up-regulation of growth 
arrest and of DNA damage-inducible gene, GADD45, was observed in Caco-2 cells that received 
BGO-FFA [45]. Up-regulation of GADD45 mRNA in the Caco-2 cells treated with BGO-FFA was 
induced in a dose-dependent manner [45]. Up-regulation of p53 mRNA was also observed in Caco-2 
cells treated with BGO-FFA [45]. Takekawa and Saito [80] identified GADD45 as a critical mediator 
of apoptosis triggered by the activation of JNK and/or p38, via MTK1/MEKK4 MAPK signaling 
pathways. GADD45 is also a target gene induced by the p53 tumor suppressor [81]. Although  
down-stream signaling from GADD45 that is affected by BGO-FFA is still unknown, we suspected 
that up-regulation of GADD45 and p53 contributes to apoptosis induction in Caco-2 cells treated  
with BGO-FFA. 
5. Conclusion and Future Perspectives 
CFA, such as CLA, CLN, and other polyenoic fatty acids, are indisputably reported to be novel 
biomolecules possessing potential health benefits, but it generally only occurs in very low quantities 
(<1%) in products of natural origin. The fact that high amounts of naturally occurring CLN are present 
in certain plant seed oils suggests it is much more accessible and easily available for dietary use than 
previously thought. CLN is thus a CFA with potential use as a functional food component in 
nutraceuticals. However, increased interest in CLN as a potential biomolecule and multi-biological 
function should be corroborated with information on its oxidative stability. In conclusion, CLN has a 
great potential as an ingredient in functional and health food formulations. Further, the exact biological 
effects CLN on the pathophysiological systems must be established in respect to its oxidative stability, 
since CLN is more susceptible to oxidation than corresponding non-conjugated fatty acid, α-linolenie 
acid  [58]. Also, safety of CLN in humans [82–84]  should be confirmed if CLN is to be used as   
a nutraceutical. Int. J. Mol. Sci. 2011, 12                       
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